The debrisoquine hydroxylase (CYP2D6), which metabolizes more than 30
different drugs, is highly polymorphic, In subjects having either very
low or very high enzyme activity, drug therapy at recommended doses u
sing CYP2D6 substrates may lead to either increased risk of side effec
ts or therapeutic failure, We here describe PCR-based methods for dete
ction of alleles having either duplicated, multiduplicated or deleted
active CYP2D6 genes, As a control reaction, the entire coding region o
f the CYP2D6 gene is amplified. In conjunction with analysis of common
mutations using this product as a template, the methods described can
be used for genotyping of individuals being either poor, intermediate
rapid, normal or ultrarapid metabolizers and provides an efficient to
ol for individualization of drug therapy.